TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35428679

Group type: EXPERIMENTAL
Intervention: Text message reminders
Number of subjects: 3623

Group type: EXPERIMENTAL
Intervention: Text message reminders (in prespecified subsample)
Number of subjects: 3623

Group type: COMPARATOR
Intervention: Control group (no text message reminders)
Number of subjects: 3623
Study: 32087031

Group type: EXPERIMENTAL
Intervention: Freeze-dried German chamomile tea capsules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo capsules containing lactose
Number of subjects: 0
Study: 34111992

Group type: EXPERIMENTAL
Intervention: Landmark-guided injection of 40 mg methylprednisolone plus 1 mL lidocaine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided injection of 40 mg methylprednisolone plus 1 mL lidocaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparison between landmark-guided and ultrasonography-guided injections
Number of subjects: 50
Study: 32482541

Group type: EXPERIMENTAL
Intervention: Daratumumab, Bortezomib, and Dexamethasone (D-Vd)
Number of subjects: 498
Study: 33164580

Group type: EXPERIMENTAL
Intervention: Nicotine e‐cigarette (59 mg/mL)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo e‐cigarette (0 mg/mL)
Number of subjects: 15
Study: 33074857

Group type: EXPERIMENTAL
Intervention: Defer ART until the WHO criteria were met
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Baseline plasma biomarkers (sVCAM-1, sCD14)
Number of subjects: 477
Study: 36270493

Group type: EXPERIMENTAL
Intervention: Ticagrelor in addition to aspirin
Number of subjects: 10156

Group type: COMPARATOR
Intervention: Placebo in addition to aspirin
Number of subjects: 10156

Group type: EXPERIMENTAL
Intervention: Ticagrelor in addition to aspirin (THEMIS-PCI substudy)
Number of subjects: 10156
Study: 33962511

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT) including rib raising and suboccipital release in addition to standard asthma care.
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard care only (control group).
Number of subjects: 58
Study: 33077567

Group type: EXPERIMENTAL
Intervention: Exogenous surfactant therapy (Curosurf, Chiesi Pharmaceuticals, Italy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (air)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exogenous surfactant therapy (Curosurf)
Number of subjects: 0
Study: 34410414

Group type: EXPERIMENTAL
Intervention: Personalized antiplatelet therapy (PFT-guided)
Number of subjects: 2285

Group type: COMPARATOR
Intervention: Standard antiplatelet treatment
Number of subjects: 2285
Study: 33750034

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1000 mg twice daily for 14 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Both MMF and Placebo
Number of subjects: 32
Study: 35567420

Group type: EXPERIMENTAL
Intervention: Test product of rosuvastatin 10 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Reference product of rosuvastatin 10 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: High-fat meals
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Single dose of rosuvastatin 10 mg
Number of subjects: 28
Study: 34340936

Group type: EXPERIMENTAL
Intervention: Endometrial preparation with GnRH agonist pre-treatment (group A)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Endometrial preparation without GnRH agonist pre-treatment (group B)
Number of subjects: 188
Study: 35613387

Group type: EXPERIMENTAL
Intervention: HH+CO2
Number of subjects: 10

Group type: COMPARATOR
Intervention: HH
Number of subjects: 10
Study: 32376946

Group type: EXPERIMENTAL
Intervention: 333 Hz tACS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 667 Hz tACS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham-tACS
Number of subjects: 0
Study: 36182028

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 1200 mg TID
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 32839468

Group type: EXPERIMENTAL
Intervention: 20 mg hydrocortisone
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 35577483

Group type: EXPERIMENTAL
Intervention: Educational program with situational simulation video (2 weeks duration)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 100
Study: 33569560

Group type: EXPERIMENTAL
Intervention: Web-based multidomain intervention group (MIG)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 120
Study: 32961273

Group type: EXPERIMENTAL
Intervention: Anodal HD-tDCS
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 29
Study: 35268481

Group type: EXPERIMENTAL
Intervention: Subetta therapy for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35273943

Group type: EXPERIMENTAL
Intervention: Competitive risk model for predicting cancer-specific survival (CSS) in elderly patients with chRCC
Number of subjects: 3522

Group type: EXPERIMENTAL
Intervention: Decision curve analysis (DCA) model
Number of subjects: 3522
Study: 33548429

Group type: EXPERIMENTAL
Intervention: Natural Language Processing (NLP) algorithm for detecting AAAs
Number of subjects: 32778

Group type: EXPERIMENTAL
Intervention: Natural Language Processing (NLP) algorithm for confirming absence of AAAs
Number of subjects: 32778

Group type: EXPERIMENTAL
Intervention: Natural Language Processing (NLP) algorithm for identifying maximal aortic diameter
Number of subjects: 32778
Study: 34534272

Group type: EXPERIMENTAL
Intervention: Ciraparantag 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciraparantag 60 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciraparantag 120 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciraparantag 30 mg (rivaroxaban)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciraparantag 60 mg (rivaroxaban)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciraparantag 120 mg (rivaroxaban)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciraparantag 180 mg (rivaroxaban)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (rivaroxaban)
Number of subjects: 0
Study: 34694215

Group type: EXPERIMENTAL
Intervention: Adapted smoking cessation treatment
Number of subjects: 169
Study: 32268336

Group type: EXPERIMENTAL
Intervention: ADQI consensus conference reports
Number of subjects: 34

Group type: COMPARATOR
Intervention: Randomized trials
Number of subjects: 34
Study: 35292005

Group type: EXPERIMENTAL
Intervention: AktiFAME strategy (Active access, counseling, and case management)
Number of subjects: 9000

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 9000

Group type: EXPERIMENTAL
Intervention: AktiFAME strategy
Number of subjects: 9000
Study: 33822433

Group type: EXPERIMENTAL
Intervention: Hierarchical syntactic structure‐building Grammar (HG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nested associating Grammar (NG)
Number of subjects: 36
Study: 36307353

Group type: COMPARATOR
Intervention: Sevoflurane (group S)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol (group P)
Number of subjects: 0
Study: 33517738

Group type: EXPERIMENTAL
Intervention: 0.5% CHX (alcoholic chlorhexidine)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Dermol (DML) 500 emollient
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 116
Study: 35941622

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation sessions (twice weekly for six weeks) consisting of supervised stretching, aerobic and strengthening exercises, and patient education.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 54
Study: 34397727

Group type: EXPERIMENTAL
Intervention: Remifentanil at 1.0 ng/mL
Number of subjects: 80

Group type: COMPARATOR
Intervention: Remifentanil at 2.0 ng/mL
Number of subjects: 80
Study: 32925628

Group type: EXPERIMENTAL
Intervention: Elective labor induction at 39 weeks of gestation
Number of subjects: 5007

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 5007
Study: 33284965

Group type: EXPERIMENTAL
Intervention: ω‐3 supplementation (3 g/d)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Corn oil (placebo)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE)
Number of subjects: 23
Study: 32562884

Group type: EXPERIMENTAL
Intervention: HuCNS‐SC transplantation (0.25 × 10^6 or 1.0 × 10^6 HuCNS‐SCs infused directly into the subretinal space)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: HuCNS‐SC transplantation
Number of subjects: 15
Study: 33026449

Group type: EXPERIMENTAL
Intervention: RT plus icotinib (125 mg 3 times a day)
Number of subjects: 127

Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: RT plus icotinib
Number of subjects: 127
Study: 35831629

Group type: EXPERIMENTAL
Intervention: Slow eccentric/fast concentric phase group (S/F; 4 s and 1 s)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fast eccentric/fast concentric phase group (F/F; 1 s both phases)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (F/F and S/F)
Number of subjects: 20
Study: 32737064

Group type: EXPERIMENTAL
Intervention: Participation in multiple neonatal clinical trials
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Perceived risks and benefits of each individual study
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Parental autonomy in decision-making
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Awareness of parental feelings
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Capacity to remember details of multiple studies
Number of subjects: 17
Study: 32740079

Group type: EXPERIMENTAL
Intervention: Low-volume same-day PEG (15 mg bisacodyl the day before, 2 L the morning of the procedure)
Number of subjects: 1750

Group type: EXPERIMENTAL
Intervention: High-volume split-dose PEG (2 L + 2 L)
Number of subjects: 1750

Group type: EXPERIMENTAL
Intervention: Low-volume split-dose PEG (15 mg bisacodyl the day before, 1 L + 1 L)
Number of subjects: 1750

Group type: EXPERIMENTAL
Intervention: Low-volume same-day PEG
Number of subjects: 1750

Group type: EXPERIMENTAL
Intervention: Low-volume split-dose PEG
Number of subjects: 1750

Group type: EXPERIMENTAL
Intervention: High-volume split-dose PEG
Number of subjects: 1750
Study: 36410811

Group type: EXPERIMENTAL
Intervention: BCG vaccination available every day at health facility contact
Number of subjects: 23

Group type: COMPARATOR
Intervention: Current practice of BCG vaccination
Number of subjects: 23
Study: 33607823

Group type: EXPERIMENTAL
Intervention: External application of mirabilite and rhubarb combined with intrathoracic chemotherapy (cisplatin)
Number of subjects: 84
Study: 34532785

Group type: EXPERIMENTAL
Intervention: Programmed intermittent epidural bolus (PIEB) 3 mL bolus every 60 min
Number of subjects: 58

Group type: COMPARATOR
Intervention: Continuous epidural infusion (CEI) 3 mL/h
Number of subjects: 58
Study: 32406659

Group type: EXPERIMENTAL
Intervention: Implant-supported fixed complete dentures
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional complete dentures
Number of subjects: 20
Study: 33328057

Group type: EXPERIMENTAL
Intervention: Electronic decision support (rehydration calculator)
Number of subjects: 4975

Group type: COMPARATOR
Intervention: Paper formatted WHO guidelines
Number of subjects: 4975
Study: 36102447

Group type: EXPERIMENTAL
Intervention: Q-switched laser
Number of subjects: 45

Group type: COMPARATOR
Intervention: TCA peeling
Number of subjects: 45

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 45
Study: 32619057

Group type: EXPERIMENTAL
Intervention: Opalescence PF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opalescence Go
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 32144189

Group type: EXPERIMENTAL
Intervention: Exercise intervention (four supervised sessions and home-based exercises)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 235

Group type: COMPARATOR
Intervention: Control group (health education programme only)
Number of subjects: 235
Study: 35120162

Group type: EXPERIMENTAL
Intervention: YOGA
Number of subjects: 60

Group type: COMPARATOR
Intervention: CON
Number of subjects: 60
Study: 33447861

Group type: EXPERIMENTAL
Intervention: Preoperative radiomics-based nomogram using random forest
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Preoperative radiomics-based nomogram using logistic regression
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: MVI-positive (M2 and M1) patients
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: MVI-negative (M0) patients
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Preoperatively predicted MVI by MVI nomogram using random forest
Number of subjects: 356
Study: 34370166

Group type: EXPERIMENTAL
Intervention: Mobile health educational intervention via WhatsApp messenger for 7 weeks on a daily schedule
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no messages received)
Number of subjects: 38
Study: 33300183

Group type: EXPERIMENTAL
Intervention: D/C/F/TAF 800/150/200/10 mg
Number of subjects: 1840

Group type: EXPERIMENTAL
Intervention: D/C/F/TAF
Number of subjects: 1840
Study: 32614482

Group type: EXPERIMENTAL
Intervention: Brief self‐compassion intervention (two 2.5‐h sessions)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 27
Study: 35691295

Group type: EXPERIMENTAL
Intervention: FINLAY-FR-1A vaccine (50 μg of recombinant dimeric receptor binding domain [RBD])
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: FINLAY-FR-1A vaccine
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo (vaccine excipient)
Number of subjects: 450
Study: 33742194

Group type: EXPERIMENTAL
Intervention: Combined aerobic exercise and diet
Number of subjects: 1401

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1401

Group type: COMPARATOR
Intervention: Aerobic exercise alone
Number of subjects: 1401

Group type: COMPARATOR
Intervention: Resistance exercise alone
Number of subjects: 1401

Group type: COMPARATOR
Intervention: Resistance exercise with a healthy diet
Number of subjects: 1401
Study: 32515703

Group type: EXPERIMENTAL
Intervention: Preventive counseling with a nutritional component and distant support via telephone (6 consultations over 3 months)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard counseling by a health center physician
Number of subjects: 100
Study: 34353299

Group type: EXPERIMENTAL
Intervention: KIND challenge (doing at least one act of kindness per week for four weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study: 33023516

Group type: EXPERIMENTAL
Intervention: Low risk scenario
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: Average risk scenario
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: Moderate risk scenario
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: High risk scenario
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: General interest in breast cancer risk
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: First degree family history of breast cancer
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: General beliefs about medication
Number of subjects: 942
Study: 35074603

Group type: EXPERIMENTAL
Intervention: Indirect Basophil Activation Test (BAT) for peanut extract, Ara h2, and Ara h6
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Indirect Basophil Activation Test (BAT) for Ara h2
Number of subjects: 74

Group type: COMPARATOR
Intervention: Double-blind placebo-controlled food challenge (OFC)
Number of subjects: 74
Study: 36403580

Group type: EXPERIMENTAL
Intervention: Propranolol plus standard care
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 83
Study: 33455820

Group type: EXPERIMENTAL
Intervention: COOK Zenith p‐Branch OTS device
Number of subjects: 23
Study: 33067298

Group type: EXPERIMENTAL
Intervention: Usual care plus an enhanced rehabilitation programme (patient-held information workbook, goal setting diary, up to six additional therapy sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Usual care plus an enhanced rehabilitation programme (intervention)
Number of subjects: 0
Study: 34387261

Group type: EXPERIMENTAL
Intervention: Community-based participatory research (CBPR)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Traditional research
Number of subjects: 98
Study: 32785589

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin/relebactam 500 mg/500 mg/250 mg
Number of subjects: 537

Group type: COMPARATOR
Intervention: Piperacillin/tazobactam 4 g/500 mg
Number of subjects: 537
Study: 35113923

Group type: EXPERIMENTAL
Intervention: Patient perspectives on factors influencing RCT recruitment
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Staff perspectives on factors influencing RCT recruitment
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Overall recruitment strategies
Number of subjects: 36
Study: 33011874

Group type: EXPERIMENTAL
Intervention: COSMED K5 portable metabolic system
Number of subjects: 27
Study: 36202335

Group type: EXPERIMENTAL
Intervention: High symptom burden group (n=20, 45.5%)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Low symptom burden group (n=24, 54.5%)
Number of subjects: 44
Study: 33122393

Group type: EXPERIMENTAL
Intervention: MCSFA-HFD (diet enriched with ∼30 g (5E%) saturated MCFAs)
Number of subjects: 17

Group type: COMPARATOR
Intervention: LCSFA-HFD (high-fat diet enriched with saturated long-chain fatty acids)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: MCSFA-HFD
Number of subjects: 17
Study: 35339715

Group type: EXPERIMENTAL
Intervention: Linezolid-based regimen (including levofloxacin, pyrazinamide, thioisonicotinamide, amikacin sulfate, sodium p-amino salicylate)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Linezolid-based regimen
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (without linezolid)
Number of subjects: 50
Study: 33843789

Group type: EXPERIMENTAL
Intervention: Intravenous estrogen (25 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 40
Study: 33246506

Group type: EXPERIMENTAL
Intervention: Higher maternal education
Number of subjects: 3578

Group type: EXPERIMENTAL
Intervention: Birth interval of at least 2 years
Number of subjects: 3578

Group type: EXPERIMENTAL
Intervention: Intended conception of the child
Number of subjects: 3578

Group type: EXPERIMENTAL
Intervention: Maternal exposure to physical violence
Number of subjects: 3578

Group type: EXPERIMENTAL
Intervention: Age of child (18-23 months)
Number of subjects: 3578

Group type: EXPERIMENTAL
Intervention: Male child
Number of subjects: 3578
Study: 36356632

Group type: EXPERIMENTAL
Intervention: aprocitentan 12·5 mg
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: aprocitentan 25 mg
Number of subjects: 730

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 730
Study: 33470031

Group type: EXPERIMENTAL
Intervention: 1.1 GBq radioiodine therapy
Number of subjects: 474

Group type: COMPARATOR
Intervention: 3.7 GBq radioiodine therapy
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 474
Study: 32384056

Group type: EXPERIMENTAL
Intervention: Horyzons, a long-term social media-based mental health intervention
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Horyzons
Number of subjects: 12
Study: 35927733

Group type: EXPERIMENTAL
Intervention: Weekly saline (0.9%) washout in addition to standard LTC care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weekly citric acid (3.23%) washout in addition to standard LTC care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard LTC care only
Number of subjects: 0
Study: 33883252

Group type: EXPERIMENTAL
Intervention: Vadadustat
Number of subjects: 304
Study: 35671941

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Combined General Anesthesia with Thoracic Epidural (GA + TEA)
Number of subjects: 38
Study: 34881696

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Number of subjects: 5769

Group type: COMPARATOR
Intervention: Ticagrelor plus aspirin
Number of subjects: 5769
Study: 32053841

Group type: EXPERIMENTAL
Intervention: Spironolactone (50 mg/d)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg/d)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/d)
Number of subjects: 99
Study: 34806783

Group type: EXPERIMENTAL
Intervention: Galcanezumab 300 mg monthly for 12 weeks
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study: 33704680

Group type: EXPERIMENTAL
Intervention: Chronic hypoparathyroidism
Number of subjects: 48582

Group type: COMPARATOR
Intervention: Control group (without hypoparathyroidism)
Number of subjects: 48582

Group type: EXPERIMENTAL
Intervention: Chronic hypoparathyroidism with kidney imaging
Number of subjects: 48582

Group type: COMPARATOR
Intervention: Control group with kidney imaging
Number of subjects: 48582
Study: 33035274

Group type: EXPERIMENTAL
Intervention: GeneXpert HIV‐1 Qual
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Alere m‐PIMA
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: At birth POC testing
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: At birth and 6-week POC testing
Number of subjects: 626
Study: 35171234

Group type: EXPERIMENTAL
Intervention: Pulmonary metastasectomy (PM)
Number of subjects: 62
Study: 32894809

Group type: EXPERIMENTAL
Intervention: High triglyceride group
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: Low high-density lipoprotein group
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: High low-density lipoprotein group
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: High triglyceride group in non-obese men
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: High triglyceride group in obese women
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: Hypertriglyceridemia
Number of subjects: 898
Study: 36367721

Group type: EXPERIMENTAL
Intervention: True Acupuncture (TA)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Sham Acupuncture (SA)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Waiting List Control (WC)
Number of subjects: 226